secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009480
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen FY2022 net loss $69.1M, cash $181.8M; Phase 2 trials planned for 2023
----------------------------------------------------------------------------

- Net loss $14.9M in Q4 2022, $69.1M for full year 2022 (vs $27.3M in 2021).
- Cash and cash equivalents $181.8M as of Dec 31, 2022; expected to fund operations into early 2025.
- R&D expenses $54.1M in FY2022 (vs $19.0M in 2021) driven by PGN-EDO51 and PGN-EDODM1 programs.
- Anticipates initiating CONNECT1-EDO51 (Phase 2 open-label) in H1 2023 and CONNECT2-EDO51 (randomized) in H2 2023.
- Phase 1 FREEDOM-DM1 trial for myotonic dystrophy type 1 expected to start H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/0000950170-23-009480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023009480/pepg-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer